Poland· PL-100424725
Pitamet
A pitavastatin product containing pitavastatinum, registered in Poland by Teva B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Pitavastatin is registered in 12 of 19 countries.
Countries holding a registration under ATC C10AA08 (pitavastatin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Pitavastatin · ATC C10AA08
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Franceprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of pitavastatin costs, country by country.
Normalised to the WHO defined daily dose (2 mg), the median price runs from $0.43 in Spain to $3.35 in United States — a ×7.7 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Pitavastatin · price per daily dose (2 mg)
USD · FX 28 Sept 2026
- US United States$3.35 (acquisition cost)
- CH Switzerland$1.57
- ES Spain$0.43
The record
At a glance
URPL (Poland)- Active substance
- Pitavastatinum
- Manufacturer
- Teva B.V.
- Country
- Poland (PL)
- ATC code
- C10AA08
- ATC class
- Pitavastatin
- Defined daily dose
- 2 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 6
- gtin05909991442330
- gtin05909991442347
- gtin05909991442354
- gtin05909991442361
- gtin05909991442378
- gtin05909991442385
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
116 interactions on record for pitavastatin.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pitavastatin · interactions on record
116 records
- 7 severe
- 103 moderate
- 2 minor
Most severe, free to view
- ErythromycinJ01FA01severe
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- CiclosporinL04AD01severe
4 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pitavastatin in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPITILOXKrka, d.d., Novo mesto, Novo mesto
- SpainALIPZA 2 mg COMPRIMIDOS RECUBIERTOS CON PELICULAKowa Pharmaceutical Europe Gmbh
- SwitzerlandLivazo 2 mg, FilmtablettenRECORDATI AG
- United StatesPitavastatinAurobindo Pharma Limited
- FranceLIPPIZA 2 mg, comprimé pelliculéKOWA PHARMACEUTICAL EUROPE (ALLEMAGNE)
- FinlandLivazoKowa Pharmaceutical Europe GmbH.
- NetherlandsLivazo 2 mg filmomhulde tablettenKowa Pharmaceutical Europe GmbH
- IrelandLivazo 2mg film-coated tabletsKowa Pharmaceutical Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 19 EEA countries. Names it is sold under:
- Austria · Trolise
- Bulgaria · Липоканте, Питавиа
- Cyprus · Vaspit
- Czechia · Pitilox
- Germany · Livazo, Pitavastatin
- Spain · Alipza, Lipix
- France · Lippiza, Trolise
- Greece · Fiarat, Livazo
- Hungary · Pitilox
- Ireland · Livazo
- Italy · Livazo
- Lithuania · Pitipix
- Malta · Vaspit
- Netherlands · Livazo
- Norway · Livazo
- Portugal · Alipza, Livazo
- Romania · Pitipix
- Slovenia · Pitipix
- Slovakia · Pitipix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cf133583-deaf-46e0-aad9-eb0f593bf048 GET /v1/drugs/cf133583-deaf-46e0-aad9-eb0f593bf048?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "2 mg",
"packaging": "05909991442330 ¦ Rp ¦ Skasowane ¦ 138359\n7 tabl. w blistrze\n05909991442347 ¦ Rp ¦ Skasowane ¦ 138360\n7 tabl. w blistrze perforowanym\n05909991442354 ¦ Rp ¦ Skasowane ¦ 138361\n28 tabl. w blistrze\n05909991442361 ¦ Rp ¦ Skasowane ¦ 138362\n28 tabl. w blistrze perforowanym\n05909991442378 ¦ Rp ¦ 138363\n30 tabl. w blistrze perforowanym\n05909991442385 ¦ Rp ¦ 138364\n30 tabl. w blistrze",
"substance": "Pitavastinum calicum 2 mg",
"common_name": "Pitavastatinum",
"pl_product_id": "100424725",
"pozwolenie_nr": "26130",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about pitavastatin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.